Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBIT Margin: 2022-2025

Historic EBIT Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to 226,826.67%.

  • Taysha Gene Therapies' EBIT Margin rose 22827510.00% to 226,826.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,622.40%, marking a year-over-year decrease of 73714.00%. This contributed to the annual value of -1,097.55% for FY2024, which is 62872.00% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' EBIT Margin is 226,826.67%, which was up 16,938.40% from -1,347.08% recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year EBIT Margin high stood at 226,826.67% for Q3 2025, and its period low was -1,915.38% during Q2 2024.
  • In the last 3 years, Taysha Gene Therapies' EBIT Margin had a median value of -930.54% in 2025 and averaged 19,760.44%.
  • Per our database at Business Quant, Taysha Gene Therapies' EBIT Margin tumbled by 774,041bps in 2023 and then surged by 22,827,510bps in 2025.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' EBIT Margin stood at 4,135.33% in 2022, then plummeted by 458,610bps to -450.78% in 2023, then plummeted by 53,498bps to -985.76% in 2024, then skyrocketed by 22,827,510bps to 226,826.67% in 2025.
  • Its last three reported values are 226,826.67% in Q3 2025, -1,347.08% for Q2 2025, and -930.54% during Q1 2025.